Biotech

Novo Nordisk's Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say

JPMorgan Lifts Acadia Price Target After Nuplazid Patent Victory

Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?

JPMorgan Lifts Acadia Price Target After Nuplazid Patent Victory

Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?

Arcutis Unveils Long-Term Efficacy, Safety For Zoryve Cream In Pediatric Patients With Atopic Dermatitis

Pfizer, Arvinas Partnered Breast Cancer Drug Cuts Progression Risk By 43% In Trial, Seeks FDA Approval

Arcutis Unveils Long-Term Efficacy, Safety For Zoryve Cream In Pediatric Patients With Atopic Dermatitis

Pfizer, Arvinas Partnered Breast Cancer Drug Cuts Progression Risk By 43% In Trial, Seeks FDA Approval

Valneva's Chikungunya Vaccine Advances With Pediatric Trial, Phase 3 In 2026

MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients

Biotech Recent News

Gilead's HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S. PrEP users by 2035.

Moderna Beats Alnylam Appeal In COVID Vaccine Patent Case

The Federal Circuit upheld a ruling that Moderna's COVID-19 vaccine does not infringe Alnylam's mRNA patents related to the SM-102 lipid used in Spikevax.

Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer

RegenXBio's RGX-202 gene therapy improved function in Duchenne patients at 9 and 12 months, supporting a 2026 BLA filing and 2027 launch.

Corcept Therapeutics Therapy Fails Primary Goal But Extends Patient Survival In Amyotrophic Lateral Sclerosis Study

Corcept's ALS drug dazucorilant improved survival despite missing the main goal; ovarian cancer drug combo met its target in Phase 3.

Sinotau Aims To Be Hong Kong's 'First Nuclear-medicine Stock'

EXCLUSIVE: Telomir Pharmaceuticals Lead Drug Shows Promising Signs In Animal Study For Rare Premature Aging Disorder

Telomir-1 boosted telomere length, restored weight and muscle, and cut oxidative stress in a preclinical Werner Syndrome animal model.

Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang

Zydus acquires two Agenus biologics facilities in California for $75 million, expanding U.S. CDMO presence and securing rights to key cancer drug manufacturing.

AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point

Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38.

Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial

Sionna's CF drug candidates SION-719 and SION-451 showed strong safety and PK results in Phase 1 trials, advancing to mid-stage studies in 2025.

Why Is Sharps Technology Stock Soaring On Wednesday?

Sharps Technology begins shipping smart syringes from Hungary facility, using new automation to meet rising global demand in 2025.

What's Behind Cellectar Biosciences' Stock Surge? FDA Update Explained

Cellectar's Iopofosine I 131 earned FDA breakthrough therapy designation for relapsed Waldenstrom macroglobulinemia following strong trial data.

Mounjaro Maker Eli Lilly Taps Swedish Firm Camurus To Target Long-Acting Obesity Market In $870-Million Deal

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies targeting metabolic diseases.

Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Trial In China, Stock Jumps

Denifanstat showed positive Phase 3 results in acne, meeting all goals with strong safety, as Sagimet pushes ahead with a second FASN inhibitor trial.